P&G’s Wellness Focus Grows Following US$3.8bn Thorne Deal
Procter & Gamble (P&G) said it will expand its health care and wellness portfolio after agreeing to buy Thorne for US$3.8bn. P&G plans to broaden a portfolio that includes Vicks, Crest, Oral-B and supplements such as Align Probiotic. Thorne’s revenue rose from about US$229m (2022) to over US$500m (2025), with US$650m targeted in 2026; deal closes later in 2026 pending approvals.
How this was made
The 30-second read
Why it matters
The disclosed purchase price, Thorne’s revenue trajectory, and consumer subscription mix provide a basis to model future earnings contribution and M&A risk, while the stated 2026 closing window frames the timeline for regulatory and integration milestones.
Market read
Material M&A headline for P&G with concrete deal economics and strategic rationale tied to self-care and personalized wellness demand.
What to watch
Regulatory approval risk and potential channel conflicts (practitioner-led brand vs P&G’s scale distribution) could delay synergies and affect deal spread pricing.
Background
P&G is expanding beyond traditional OTC and oral care into a broader health and wellness platform via the Thorne acquisition.
Ticker impact
P&G will acquire Thorne for US$3.8bn to expand its health care and wellness portfolio, with close expected later in 2026.
Moderately positive bias, with volatility around deal-regulatory headlines and integration expectations.
The article discloses a specific $3.8bn acquisition, strategic rationale (self-care, preventive, personalized wellness), and a stated closing window subject to regulatory approvals, which can re-rate growth assumptions and M&A risk premium.
Market effects
Signals continued consolidation and premiumization in vitamins, minerals, and supplements, potentially raising competitive intensity for specialist supplement brands.
Limited direct regional read-through; primarily global consumer health and M&A sentiment.
Large US$3.8bn cross-category deal reinforces global wellness demand narrative and may influence dealmaking appetite across North America and Europe.
Counterpoint
The acquisition may be value-dilutive if Thorne’s growth rate normalizes post-deal or if integration costs outweigh the wellness premium.
Key entities
- companyProcter & Gamble
US consumer goods company acquiring Thorne to expand health care and wellness offerings.
- companyThorne
Science-backed supplement and wellness brand being acquired for US$3.8bn.
- private_firmL Catterton
Investment firm selling Thorne via its Flagship Fund.
